HomeCompareERVFF vs ABBV

ERVFF vs ABBV: Dividend Comparison 2026

ERVFF yields 7692.31% · ABBV yields 3.12%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ERVFF wins by $4177739098279589.00M in total portfolio value
10 years
ERVFF
ERVFF
● Live price
7692.31%
Share price
$0.03
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4177739098279589.00M
Annual income
$4,073,565,928,588,968,500,000.00
Full ERVFF calculator →
ABBV
AbbVie Inc.
● Live price
3.12%
Share price
$213.22
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$104.7K
Annual income
$25,725.73
Full ABBV calculator →

Portfolio growth — ERVFF vs ABBV

📍 ERVFF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodERVFFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ERVFF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ERVFF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ERVFF
Annual income on $10K today (after 15% tax)
$653,846.15/yr
After 10yr DRIP, annual income (after tax)
$3,462,531,039,300,623,000,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$265.10/yr
After 10yr DRIP, annual income (after tax)
$21,866.87/yr
At 15% tax rate, ERVFF beats the other by $3,462,531,039,300,623,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ERVFF + ABBV for your $10,000?

ERVFF: 50%ABBV: 50%
100% ABBV50/50100% ERVFF
Portfolio after 10yr
$2088869549139794.50M
Annual income
$2,036,782,964,294,484,200,000.00/yr
Blended yield
97.51%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

ERVFF
No analyst data
Altman Z
5.3
Piotroski
1/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+20.1% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ERVFF buys
0
ABBV buys
0
No recent congressional trades found for ERVFF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricERVFFABBV
Forward yield7692.31%3.12%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$4177739098279589.00M$104.7K
Annual income after 10y$4,073,565,928,588,968,500,000.00$25,725.73
Total dividends collected$4170772265337663.00M$63.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: ERVFF vs ABBV ($10,000, DRIP)

YearERVFF PortfolioERVFF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$779,931$769,230.77$11,559$438.51+$768.4KERVFF
2$56,904,315$56,069,789.30$13,494$640.86+$56.89MERVFF
3$3,884,151,673$3,823,264,055.84$15,951$945.97+$3884.14MERVFF
4$248,050,254,929$243,894,212,638.74$19,152$1,413.89+$248050.24MERVFF
5$14,822,056,221,428$14,556,642,448,653.80$23,443$2,146.38+$14822056.20MERVFF
6$828,776,618,419,079$812,917,018,262,150.50$29,391$3,321.96+$828776618.39MERVFF
7$43,367,472,132,823,630$42,480,681,151,115,220.00$37,948$5,265.87+$43367472132.79MERVFF
8$2,123,871,047,251,591,000$2,077,467,852,069,469,400.00$50,795$8,596.74+$2123871047251.54MERVFF
9$97,358,102,514,598,310,000$95,085,560,494,039,100,000.00$71,034$14,549.41+$97358102514598.25MERVFF
10$4,177,739,098,279,589,000,000$4,073,565,928,588,968,500,000.00$104,715$25,725.73+$4177739098279589.00MERVFF

ERVFF vs ABBV: Complete Analysis 2026

ERVFFStock

Erin Ventures Inc. is an emerging international junior mining and exploration company engaged in the acquisition, exploration, and development of precious metal properties. Erin Venture's strategy is to uncover and capitalize on unique development opportunities within different regions internationally. The Company's objective is to increase its mineral reserves by developing current properties and through the acquisition of additional mining projects. We are expanding exploration activities at both our Ceibo Chico gold property in Belize, and our Deep River gold project in North Carolina and expect to offset costs on both properties through recently established gold production.

Full ERVFF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this ERVFF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ERVFF vs SCHDERVFF vs JEPIERVFF vs OERVFF vs KOERVFF vs MAINERVFF vs JNJERVFF vs MRKERVFF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.